Pretreatment with Oral Anticoagulants Decreases Platelet Activation in Patients Before and After Percutaneous Coronary Intervention

Summary

Background

Platelet activation plays a major role in acute vessel closure after coronary angioplasty. In the randomized Balloon Angioplasty and Anticoagulation Study (BAAS), pretreatment with oral anticoagulants in addition to aspirin resulted in a 47% reduction of acute complications as compared with aspirin alone. This result may suggest a direct effect of oral anticoagulants on platelet activation.

Methods and Results

Patients were randomized to aspirin alone (group A, n = 26) or to aspirin plus oral anticoagulants started one week before angioplasty (group B, n = 26). Platelet response tests were performed 1 hour before (baseline) and 1 hour after intervention and on day 1. Platelet activation was measured by flow cytometry, as the number of antibody-positive platelets per 10,000 counted. Platelet function was evaluated with use of the PFA-100® analyzer. In group B, the median number of P-selectin-positive platelets was lower before (28 vs. 54, P = 0.018) and after (13 vs. 24, P = 0.377) angioplasty than in group A. Also the median decrease in the number of P-selectin-positive platelets during angioplasty was lower in group B (Δ = 4) than in group A (Δ = 30, P = 0.022). No further significant change was observed in platelet activation on day 1 in the two groups. The ability of platelets to become stimulated as measured with the PFA-100® analyzer was not affected by oral anticoagulants.

Conclusions

Pretreatment with oral anticoagulants resulted in less activated platelets before and after coronary angioplasty, which is in agreement with its clinical effect of reducing procedural complications. Platelet function was not affected by oral anticoagulants.

Keywords

Percutaneous coronary intervention - platelets - oral anticoagulants - flow cytometry - PFA-100® analyzer

• References

• 1 Mruk JS, Chesebro JH, Webster MWI. Platelet aggregation and interaction with the coagulation system: implications for antithrombotic therapy in arterial thrombosis. Coronary Artery Dis 1990; 01: 149-55.
• 2 Mizuno O, Hojo Y, Ikeda U, Katsuki T, Fakazawa H, Kirosaki K, Fujikawa H, Shimada K. Assessment of coagulation and platelet activation on coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000; 85: 154-60.
• 3 Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Umans VAWM, Fox KAA, Close P, Deckers JW. for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995; 333: 757-63.
• 4 Bittl JA, Chaitman BR, Feit F. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001 (in press).
• 5 ten Berg JM, Kelder JC, Suttorp MJ, Mast EG, Bal E, Ernst SMPG, Verheugt FWA, Plokker HWM. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000; 102: 386-91.
• 6 Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-36.
• 7 Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100TM system: a new method for assessment of platelet dysfunction. Sem Thromb Hemost 1998; 24: 195-202.
• 8 Beaumont van W. Evaluation of hemoconcentration from hematocrit measurements. J Appl Physiol 1972; 32: 712-3.
• 9 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 2000; 102: 1931-6.
• 10 Merten M, Chow T, Hellums D, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation 2000; 102: 2045-50.
• 11 Colman RW, Hirsh J, Marder VJ, Salzman EW. Hemostasis and Thrombosis. 3rd ed. 1994
• 12 Kolarov P, Tschoepe D, Nieuwenhuis HK, Gries FA, Strauer B, Schultheiß HP. PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA Platelet Study (DPPS). Eur Heart J 1996; 17: 1216-22.
• 13 Tschoepe D, Schultheiß HP, Kolarov P, Schwippert B, Dannehl K, Volksw D, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 37-42.
• 14 Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-6.
• 15 Taylor ML, Ilton MK, Misso NLA, Watkins DN, Hung J, Thompson PJ. The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils. Br J Clin Pharmacol 1998; 46: 139-45.
• 16 Ortel TL, James AH, Thames EH, Moore KD, Greenberg CS. Assessment of primary hemostasis by PFA-100® analysis in a tertiary care center. Thromb Haemost 2000; 84: 93-7.
• 17 Gawaz M, Neumann FJ, Ott I, Rudiger S, Schömig A. Changes in membrane glycoproteins in circulating platelets after coronary stent implantation. Heart 1996; 76: 166-72.
• 18 Knight CJ, Panesar M, Wilson DJ, Patrineli A, Chronos N, Wright C, Clarke D, Patel D, Fox K, Goodall AH. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis. Eur Heart J 1998; 19: 1239-48.
• 19 Michelson AD, Bernard MR, Hechtman HB, MacGregor H, Connolly R, Loscalzo J, valeri CR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996; 93: 11877-82.
• 20 Gawaz M, Neumann F-J, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-85.
• 21 Merlini PA, Ardissino D, Bauer KA, Oltrona L, Pezzano A, Bottasso B, Rosenberg RD, Mannucci PM. Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Circulation 1997; 17: 1325-30.
• 22 Thompson C, Forbes CD, Prentice CRM. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973; 45: 485-94.
• 23 Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecularweight heparin and with a direct thrombin inhibitor. Circulation 1999; 97: 251-6.
• 24 Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000; 139: 696-703.
• 25 Fluck DS, Chenu P, Mills P, Davies A, Street J, Paul E, Balcon R, Layton CA. for the Widest Trial Investigators’ Group. Is provisional stenting the effective option? The WIDEST study (Wiktor in the novo stenosis). Heart 2000; 84: 522-28.
• 26 Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, Colombo A. on behalf of the DESTINI Study Group. Randomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. Circulation 2000; 102: 2938-44.
• 27 Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger J, Buller N, Bonser R, van den Brand MJB, van Herwerden LA, Morel M-AM, van Hout BA. bfor the Arterial revascularization therapies study group. N Engl J Med 2001; 344: 1117-24.
• 28 Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.